ReviewCancer management and research2025
The Role of Cavin3 in the Development of Malignant Tumors.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Study on the Expression Level of CAVIN3 Gene and the Prognosis of Radiotherapy in Patients with Cervical Cancer.Cancers · 2026Article
- Caveolae in cancer: mechanochemical signaling in tumor progression, immunity, and therapy.Cell communication and signaling : CCS · 2026Review
- Integrated Proteomic and Metabolomic Analyses Characterise Molecular Alterations Associated with JSRV-Induced OPA.Biology · 2026Article
- Cavin gene family and caveolae-related disorders: pathogenetic roles and possible mechanisms.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cavin3, also known as PRKCDBP or SRBC, is an important member of the Cavin family. It plays a crucial role in the formation and functional regulation of caveolae while also acting as a tumor suppressor in the occurrence and development of most malignant tumors, primarily regulated by promoter region methylation. This paper systematically reviews the research progress of Cavin3 in breast cancer, lung cancer, gastric cancer, colorectal cancer and gynecological tumors, focusing on the role of Cavin3 in tumor prognosis and its possible regulatory mechanism. Current studies have shown that in breast cancer and lung cancer, Cavin3 can exert anti-tumor effects by inhibiting the PI3K/AKT signaling pathway and participating in DNA damage repair. In gastric cancer, it mainly activates downstream pathways by stabilizing p53, inducing cell cycle arrest and apoptosis. However, the specific role of Cavin3 in other tumor types and its broader regulatory mechanism have not yet been fully clarified and further in-depth research is needed. Future research on Cavin3 may provide new insights and effective strategies for precision diagnosis and treatment of malignant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.